Latest Biotech News

Eikon Therapeutics, a protein-dynamics drug developer founded by former Merck executives, signaled plans to go public and to use proceeds to fund a clutch of oncology and neuroscience programs....

Teva Pharmaceuticals agreed a financing arrangement with Royalty Pharma that could provide up to $500 million to support development of TEV-‘408, an anti–IL‑15 antibody being tested for vitiligo....

Tempus reported preliminary fourth-quarter revenue of approximately $367 million, an 83% year-over-year increase driven by diagnostics volume growth in oncology and hereditary disease testing. The...

Guardant Health reported preliminary fourth-quarter revenue of roughly $280 million, a 39% increase year over year driven by higher volumes in oncology testing and rapid uptake of its Shield...

Parabilis Medicines closed a $305 million Series F financing led by RA Capital, Fidelity Management & Research, and Janus Henderson to advance zolucatetide (FOG-001) into Phase III for desmoid...

Eikon Therapeutics outlined plans to go public after raising more than $1 billion in private funding since 2019 and building a drug portfolio from dealmaking and its protein-motion platform. Run...

Mirador Therapeutics closed a $250 million Series B to scale development of precision medicines for immune diseases and signaled consideration of an IPO later this year. The company told Endpoints...

Tempus reported preliminary fourth‑quarter revenue of roughly $367 million, an 83% increase year‑over‑year, citing testing growth as the primary driver and topping Wall Street estimates. The...

Guardant Health reported preliminary Q4 revenue of about $280 million, a 39% year‑over‑year increase that beat estimates, driven by higher volumes in both oncology and screening tests. The company...

Veracyte reported preliminary Q4 revenue between $138 million and $140 million (16–18% growth) and full‑year 2025 revenue of $515–517 million, driven by testing volume gains. The diagnostic firm...

10x Genomics said preliminary Q4 revenue of $166 million — ahead of consensus — with consumables revenue rising about 6% to approximately $141.7 million while instrument revenue declined sharply...

Castle Biosciences expects preliminary full‑year 2025 revenue of $340 million, above prior guidance and consensus, driven by a 37% year‑over‑year increase in test reports. The company delivered...

Xella Health raised $3.7 million in a pre‑seed round led by Precursor Ventures to develop a multiomic women's precision health and diagnostics platform combining at‑home sample collection...

The NIH announced that the federal SBIR and STTR programs expired effective immediately, halting non‑dilutive seed funding across agencies including HHS, Agriculture, Commerce, Energy and Defense....

Eikon Therapeutics filed for an initial public offering after raising more than $1 billion in private capital since 2019. The company, founded and led by former Merck executives including...

Mirador Therapeutics closed a $250 million Series B to accelerate development of precision medicines for immune diseases and signaled plans to consider an IPO later this year. The financing...

Researchers in China unveiled DrugCLIP, an AI framework that the team says can screen millions of candidate compounds against thousands of protein targets in just hours—described as...

Anthropic has moved into healthcare product offerings, mirroring OpenAI’s push but taking a different product architecture: Anthropic is blending enterprise and consumer tools into a single...

The NIH issued a notice that the SBIR and STTR programs have expired "effective immediately," pausing a major federal source of non-dilutive seed funding for life‑science startups. The lapse...

Stoke Therapeutics reported that the FDA declined to agree to an accelerated filing for zorevunersen, its experimental treatment for Dravet syndrome, after a December meeting. Regulators did not...